apixaban (Eliquis)

Bristol-Myers Squibb · F10 · Small Molecule

Status

✓ Approved

Indications

5 conditions

Clinical Trials

24 total

Targets

F10

What is apixaban?

Last updated: February 2025

apixaban is a small molecule developed by Bristol-Myers Squibb. It is approved for therapeutic indications via oral (po).

apixaban acts on 1 molecular target:

F10	coagulation factor X (FXA, FX)

Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

There are currently 24 clinical trials registered

Trial ID	Phase	Title	Status
NCT07404345	Phase 4	Efficacy of Low-Dose Apixaban Added to Standard Heparin Lock to Prevent Dysfunction of Tunneled Hemo	● Not Yet Recruiting
NCT06953726	Phase 4	CSP #2037T - Veterans Affairs Learning Health System Initiative to Assess Novel Screening vs. Usual	● Not Yet Recruiting
NCT04809818	Phase 1	Double-Blind, Randomized, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, an	Completed
NCT07175428	Phase 2	A Phase 2, Randomized, Multicenter, Open-label, Blinded-endpoint Study to Evaluate the Safety of REG	● Recruiting
NCT07005024	Phase 3	A Comparison of Anticoagulant Dosing Strategies to Reduce VTE and Mortality in Cancer Outpatients: A	● Recruiting
NCT07015905	Phase 3	A Phase 3, Multicenter, Randomized, Open-Label, Sponsor-Blinded, Study to Evaluate REGN7508, A Facto	● Recruiting

+20 more trials available with free account

Analyze Full Trial DataNoah can compare efficacy across trials and generate reports.

apixaban is developed for 5 unique indications across 4 therapeutic areas.

Therapeutic Area	Condition	Phase
Vascular disorders	Venous thrombosis	✓ Approved
Respiratory, thoracic and mediastinal disorders	Pulmonary thrombosis	✓ Approved
Vascular disorders	Thrombosis	✓ Approved
Nervous system disorders	Delayed ischaemic neurological deficit	✓ Approved
Cardiac disorders	Acute coronary syndrome	Phase III